Follow us
Health News

UK to Test Psilocin-Based Drug for Major Depressive Disorder

Psilocin-Based Drug for Major Depressive Disorder
Written by PsychePen

UK’s MHRA approves a clinical trial to test a novel psilocin-based drug to Treat major depressive disorder.

Summary: The UK’s MHRA has approved a first-of-its-kind trial to test a novel psilocin-based drug, MSP-1014, for major depressive disorder. The trial, developed by Mindset Pharma, will combine dosages of the new drug with specialist therapy.


Latest News & Insights:

Want more insights on cannabis and psychedelics? Subscribe below!


UK Greenlights Trial for Psilocin-Based Drug in Major Depressive Disorder Treatment

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a first-of-its-kind trial to test a novel psilocin-based drug for major depressive disorder (MDD). The clinical trial, set to run this year, will combine dosages of a new psilocin-based drug, MSP-1014, with specialist therapy.

Have you ever felt this unique Deja-vu sensation?

MSP-1014, developed by Mindset Pharma, is a novel psilocin prodrug anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. “This is an exciting milestone as we prepare to enter our first-in-human clinical trial with our novel psilocin prodrug… [which based on preclinical data] has the potential to be a better tolerated psychedelic therapeutic compared to psilocybin,” stated Joseph Araujo, Chief Scientific Officer of Mindset Pharma.

The MHRA’s regulatory decision follows an agreement in December 2022 by Mindset Pharma and several other psychedelic drug developers to trial therapies for mental health conditions in London. This location was chosen to benefit from the UK’s drug regulatory process, which allows for fast-tracked ethics applications and combined reviews.

Tom McDonald, CEO at Clerkenwell Health, expressed excitement about the green light for the trial, which will explore an innovative treatment for a mental health condition such as MDD. Clerkenwell Health plans several other trials for the next year to “test the potential of psychedelics-related medicines for complex mental health and central nervous system conditions including alcohol use disorder and PTSD,” added McDonald.

[Source: European Pharmaceutical Review]
Parenting and Psilocybin, good/bad combination?

Subscribe to our newsletter

We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!

Simply place your email below:

.

.

AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.

Set, Setting and DNA…

Have anything to add? Your voice matters! Join the conversation and contribute your insights and ideas below.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About the author

PsychePen

PsychePen is Cannadelics' main news editor. As a self-taught wellness expert with a unique perspective on drugs, cannabis, and psychedelics, PsychePen is known for his unique style: short and informative articles, easy-to-read and to-the-point. PsychePen is also one of our most successful AI authors. so its keep on improving.